POMALİDOMİD-SİKLOFOSFAMİD-DEKSAMETAZON(PCD) PROTOKOLÜ

Kaynaklar:

1-Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010; 2010(1): 303- 309.

2-Larocca A, Montefusco V, Bringhen S, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 2013; 122(16): 2799- 2806.

3-Baz RC, Martin TG, Lin H-Y, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016; 127(21): 2561- 2568.

4-Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017; 130(8): 974- 981.

5- Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. Blood. 2018; 132(24): 2555- 2563.

6-Chen R, Wang Y, Luan C, Gao C, Zhang X, Chen B. Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis. J Cancer. 2017; 8(10): 1801- 1808.

7-Trudel S, Tessoulin B, Jullien M, et al. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. Ann Hematol. 2019; 98(6): 1441- 1447.

8- Ho Sup Lee, Kihyun Kim, Seok Jin Kim, et al. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am J Hematol. 2020 Apr;95(4):413-421.